Skip to main content
Erschienen in: Digestive Diseases and Sciences 9/2007

01.09.2007 | Original Paper

Symptomatic and Virological Response to Antiviral Therapy in Hepatitis C Associated with Extrahepatic Complications of Cryoglobulimia

verfasst von: Supriya Joshi, Magdalena Kuczynski, E. Jenny Heathcote

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2007

Einloggen, um Zugang zu erhalten

Abstract

Mixed cryoglobulins are detected in 50% of patients with hepatitis C; fortunately, few have vasculitis affecting skin, peripheral nerves, kidneys, and synovia. This study was designed to identify the natural history of symptomatic cryoglobulinemia and evaluate the response to antiviral therapy. Patients with hepatitis C complicated by symptomatic cryoglobulinemia were assessed for their disease manifestations and response to antiviral therapy. Of 83 patients identified, 56 patients with a minimum of 12 months follow-up were reviewed. Manifestations included dermatologic (75%), rheumatologic (57%), neurologic (34%), and renal (proteinuria 25%). Antiviral therapy was given to 38, of whom 9 were retreated for symptomatic and/or virological nonresponse. Antiviral therapy included interferon monotherapy (n= 8), pegylated-interferon monotherapy (n= 5), consensus-interferon (n= 2), interferon + ribavirin (n= 18), and pegylated-interferon + ribavirin (n= 14). Treatment provided sustained symptomatic response in 31 (82%) and virological response in 16 (42%) patients. Symptomatic cryoglobulinemia responds well to antiviral therapy, even when virological response is not achieved.
Literatur
1.
Zurück zum Zitat Lunel F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M, Grippon P, Hoang C, Piette JC, Huraux J-M, Opolon P (1994) Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 106:1291– 1300PubMed Lunel F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M, Grippon P, Hoang C, Piette JC, Huraux J-M, Opolon P (1994) Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 106:1291– 1300PubMed
2.
Zurück zum Zitat Lunel F, Musset L (1998) Hepatitis C virus infection and cryoglobulinemia. J Hepatol 29:848–855PubMedCrossRef Lunel F, Musset L (1998) Hepatitis C virus infection and cryoglobulinemia. J Hepatol 29:848–855PubMedCrossRef
3.
Zurück zum Zitat Kayali Z, Buckwold VE, Zimmerman B, Schmidt W (2002) Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 36:978–985PubMed Kayali Z, Buckwold VE, Zimmerman B, Schmidt W (2002) Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 36:978–985PubMed
4.
Zurück zum Zitat Tavoni A, Mosca M, Ferri C, Moriconi L, La Civita L, Lombardini F, Bombardieri S (1995) Guidelines for the management of essential mixed cryoglobulinemia. Clin Exp Rheumatol 13(Suppl):191S–195S Tavoni A, Mosca M, Ferri C, Moriconi L, La Civita L, Lombardini F, Bombardieri S (1995) Guidelines for the management of essential mixed cryoglobulinemia. Clin Exp Rheumatol 13(Suppl):191S–195S
5.
Zurück zum Zitat Ferri C, Moriconi L, Gremignai G, Migliorini P, Paleologo G, Fosella PV, Pasero G (1986) Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephron 43:246–253PubMedCrossRef Ferri C, Moriconi L, Gremignai G, Migliorini P, Paleologo G, Fosella PV, Pasero G (1986) Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephron 43:246–253PubMedCrossRef
6.
Zurück zum Zitat Abu-Shakra M, Hausmann MJ, Kachko L, Flusser D, Buskila D, Sukenik S (1998) Cyclophosphamide therapy in a patient with membranoproliferative glomerulonephritis and essential mixed cryoglobulinaemia. Clin Rheumatol 17:395–396PubMedCrossRef Abu-Shakra M, Hausmann MJ, Kachko L, Flusser D, Buskila D, Sukenik S (1998) Cyclophosphamide therapy in a patient with membranoproliferative glomerulonephritis and essential mixed cryoglobulinaemia. Clin Rheumatol 17:395–396PubMedCrossRef
7.
Zurück zum Zitat Bonomo L, Casato M, Afeltra A, Caccavo D (1987) Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 83:726–728PubMedCrossRef Bonomo L, Casato M, Afeltra A, Caccavo D (1987) Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 83:726–728PubMedCrossRef
8.
Zurück zum Zitat Durand JM, Cacoub P, Lunel-Fabiani F, Cosserat J, Cretel E, Kaplanski G, Frances C, Bletry O, Soubeyrand J, Godeau P (1998) Ribavirin in hepatitis C related cryoglobulinemia. J Rheumatol 25:1115–1117PubMed Durand JM, Cacoub P, Lunel-Fabiani F, Cosserat J, Cretel E, Kaplanski G, Frances C, Bletry O, Soubeyrand J, Godeau P (1998) Ribavirin in hepatitis C related cryoglobulinemia. J Rheumatol 25:1115–1117PubMed
9.
Zurück zum Zitat Calleja JL, Albillos A, Moreno-Otero R, Rossi I, Cacho G, Domper F, Yebra M, Escartin P (1999) Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinemia. Aliment Pharmacol 13:1179–1186CrossRef Calleja JL, Albillos A, Moreno-Otero R, Rossi I, Cacho G, Domper F, Yebra M, Escartin P (1999) Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinemia. Aliment Pharmacol 13:1179–1186CrossRef
10.
Zurück zum Zitat Donada C, Crucitti A, Donadon V, Chemello L, Alberti A (1998) Interferon alpha and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood 92:2983–2984PubMed Donada C, Crucitti A, Donadon V, Chemello L, Alberti A (1998) Interferon alpha and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood 92:2983–2984PubMed
11.
Zurück zum Zitat Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, Sabo E, Tsykounov I, Naschitz JE, Yeshurun D (2000) Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 27:2172–2178PubMed Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, Sabo E, Tsykounov I, Naschitz JE, Yeshurun D (2000) Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 27:2172–2178PubMed
12.
Zurück zum Zitat Mazzaro C, Zorat F, Caizzi M, Donada C, Di Gennaro G, Maso LD, Carniello G, Virgolini L, Tirelli U, Pozzato G (2005) Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 42:632–638PubMedCrossRef Mazzaro C, Zorat F, Caizzi M, Donada C, Di Gennaro G, Maso LD, Carniello G, Virgolini L, Tirelli U, Pozzato G (2005) Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 42:632–638PubMedCrossRef
13.
Zurück zum Zitat Musset L, Diemert MC, Taibi F, Thi Huong Du L, Cacoub P, Leger JM, Boissy G, Gaillard O, Galli J (1992) Characterization of cryoglobulins by immunoblotting. Clin Chem 38:798–802PubMed Musset L, Diemert MC, Taibi F, Thi Huong Du L, Cacoub P, Leger JM, Boissy G, Gaillard O, Galli J (1992) Characterization of cryoglobulins by immunoblotting. Clin Chem 38:798–802PubMed
14.
Zurück zum Zitat Naarendorp M, Kallecmuchikkal U, Nuovo GJ, Gorevic PD (2001) Long-term efficacy of interferon alpha for extrahepatic disease associated with hepatitis C infection. J Rheumatol 28:2466–2473PubMed Naarendorp M, Kallecmuchikkal U, Nuovo GJ, Gorevic PD (2001) Long-term efficacy of interferon alpha for extrahepatic disease associated with hepatitis C infection. J Rheumatol 28:2466–2473PubMed
15.
Zurück zum Zitat Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, Smith C, Herrera J, Tobias H, Conrad A, Schmid P, McHutchison JG (2000) Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 7:196–202PubMedCrossRef Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, Smith C, Herrera J, Tobias H, Conrad A, Schmid P, McHutchison JG (2000) Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 7:196–202PubMedCrossRef
16.
Zurück zum Zitat Cresta P, Musset L, Cacoub P, Frangeul L, Vitour D, Poynard T, Opolon P, Nguyen DT, Golliot F, Piette JC, Huraux JM, Lunel F (1999) Response to interferon alpha treatment and disappearance of cryoglobulinemia in patients infected by hepatitis C virus. Gut 45:122–128PubMedCrossRef Cresta P, Musset L, Cacoub P, Frangeul L, Vitour D, Poynard T, Opolon P, Nguyen DT, Golliot F, Piette JC, Huraux JM, Lunel F (1999) Response to interferon alpha treatment and disappearance of cryoglobulinemia in patients infected by hepatitis C virus. Gut 45:122–128PubMedCrossRef
17.
Zurück zum Zitat Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized control. Lancet 358:958–965PubMedCrossRef Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized control. Lancet 358:958–965PubMedCrossRef
18.
Zurück zum Zitat Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982PubMedCrossRef Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982PubMedCrossRef
19.
Zurück zum Zitat Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, Myers RP, Leger JM, Servan J, Piette JC (2003) Interferon alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 46:3317–3326CrossRef Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, Myers RP, Leger JM, Servan J, Piette JC (2003) Interferon alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 46:3317–3326CrossRef
20.
Zurück zum Zitat Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic hepatitis C. Lancet 352:1426–1432PubMedCrossRef Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic hepatitis C. Lancet 352:1426–1432PubMedCrossRef
21.
Zurück zum Zitat McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485–1492PubMedCrossRef McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485–1492PubMedCrossRef
22.
Zurück zum Zitat Sanchez-Tapias JM, Escartin P, Enriquez J, Moreno R, Romero-Gomez M, Barcena R, Crespo J, Andrade R, Perez R, Suarez MJ, Planas R, Sola R, Garcia-Bengoechea M, Garcia-Samaniego J, Berenguer J, Berenguer J, Montoro M, Del Olmo J, Lopez G, Tome S, Casanovas T, Castellanos G, Castro A (2004) Longer treatment duration with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) in naïve patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter TERAVIC-4 study. Hepatol 40: 218ACrossRef Sanchez-Tapias JM, Escartin P, Enriquez J, Moreno R, Romero-Gomez M, Barcena R, Crespo J, Andrade R, Perez R, Suarez MJ, Planas R, Sola R, Garcia-Bengoechea M, Garcia-Samaniego J, Berenguer J, Berenguer J, Montoro M, Del Olmo J, Lopez G, Tome S, Casanovas T, Castellanos G, Castro A (2004) Longer treatment duration with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) in naïve patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter TERAVIC-4 study. Hepatol 40: 218ACrossRef
23.
Zurück zum Zitat Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC (2005) PEGylated Interferon alfa-2b and ribavirin treatment in patients with hepatitis c virus-related systemic vasculitis. Arthritis Rheum 42:911–915CrossRef Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC (2005) PEGylated Interferon alfa-2b and ribavirin treatment in patients with hepatitis c virus-related systemic vasculitis. Arthritis Rheum 42:911–915CrossRef
Metadaten
Titel
Symptomatic and Virological Response to Antiviral Therapy in Hepatitis C Associated with Extrahepatic Complications of Cryoglobulimia
verfasst von
Supriya Joshi
Magdalena Kuczynski
E. Jenny Heathcote
Publikationsdatum
01.09.2007
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 9/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9355-2

Weitere Artikel der Ausgabe 9/2007

Digestive Diseases and Sciences 9/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.